Trust facts
1. Source: Polar Capital, as at 31 October 2024.
2. Ongoing charge are calculated at the latest published year end date, excluding any performance fees.
15.06.2010
Launch Date
MSCI All Country World Index/ Healthcare (Sterling)
Benchmark
0.87%
Ongoing charge2
0.63%
Dividend yield
£480.7m
Total net assets1
James Douglas PhD
James Douglas, PhD
James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.
Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma.
Fund Manager
Gareth joined Polar Capital in 2007 to set up the Healthcare team. Prior to Polar Capital, Gareth worked at Framlington, where he began his career in investment management in 1999. Soon afterwards, he joined the Healthcare Team in 2001 and helped launch the Framlington Biotech Fund, which he managed from 2004 until his departure.
Head of Healthcare
Gareth Powell, CFA
Gareth Powell CFA
A leading investment team
Daniel Mahony PhD
Healthcare fundamentals remain strong, with consumption of products and utilisation of services accelerating
With uncertainty in global markets and inflation remaining elevated, investors are worried about the health of their portfolios.
As a specialist healthcare investment trust, we focus on powerful growth stories, from disruptive biotech to global pharmaceuticals. With a diversified and conservative approach, the Polar Capital Global Healthcare Trust accesses multi-decade themes while expertly navigating near-term volatility with its bias to large defensive companies.
Trust highlights
Combining defensive growth with emerging innovation
No benchmark or tracking error constraints
Conviction portfolio with a large-cap bias
Managed by a team of highly experienced, seven specialists
A globally diversified investment trust seeking capital growth
Scroll down
Strong fundamentals
Damiano Soardo CFA
David joined Polar Capital in August 2013 as a portfolio manager within the Healthcare team, to launch the Polar Capital Biotechnology Fund. Prior to joining Polar Capital, David was portfolio manager of the International Biotechnology Trust at SV Life Sciences.
Previously, David spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm's venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector.
Fund Manager
David Pinniger, CFA
Deane joined Polar Capital in June 2013 and is the Lead Manager of the Polar Capital Healthcare Discovery Fund.
Prior to joining Polar Capital, Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen.
Fund Manager
Deane Donnigan, PharmD
Damiano joined the Polar Capital Healthcare team as an investment analyst in October 2020. He started at the company in 2016 as part of the Operations team before moving to the Risk team in 2019. Prior to joining Polar Capital, he worked as a technical consultant at a fintech company. Damiano has an MSc in Mathematics and Foundations of Computer Science from the University of Oxford and is a CFA charterholder.
Investment Analyst
Damiano Soardo, CFA
Leanne joined the Polar Capital Healthcare Team as an Investment Analyst in October 2024. She started at the company in 2021 in the Client Services team as part of the Investment 20/20 scheme.
Investment Analyst
Leanne Smith
Brett Pollard joined the Polar Capital Healthcare team in September 2021 as an investment analyst. Prior to Polar Capital, Brett was Managing Director of Strategy and Corporate Development at Scapa plc, with responsibility for investor relations. Since 2001 he has worked across the healthcare sector and within equity capital markets as a healthcare analyst, most recently at Numis, Brett also has worked in and led financial communications, corporate development, investor relations and operations.
Investment Analyst
Brett Pollard, PhD
Is healthcare at the heart of your portfolio?
2
Closed Ended Investment Company
Legal structure
United Kingdom
Domicile
GBP
Currency
London Stock Exchange
Listed
PCGH
Ticker
Healthcare is an incredibly diverse sector and so in any given economic, regulatory or political climate we should be able to find opportunities. At the moment, we are seeing a pick up in utilisation of healthcare services now that Covid is fully behind us, and there are multiple areas within the sector where we can expose the portfolio to that rising trend.
Fund Manager
Head of Healthcare
Consultant
Investment Analyst
Why invest in healthcare now?
We believe Healthcare is a long-term, secular growth sector as ageing populations in developed and emerging countries worldwide drive the demand and the need for increased healthcare provision.
The political conundrum is how to develop and deliver better healthcare to more people for less money. Healthcare companies with products or services that deliver demonstrable value and drive efficiency are well-placed for future growth with a number of other key, long-term drivers also propelling the sector.
The investment team that manages the Polar Capital Global Healthcare Trust was set up in 2007 and includes fund managers who held senior roles in the pharma and biotech industry – in equity sales, as a clinical specialist and a research scientist as well as time working in academic laboratories and institutes – before managing money in the sector.
Valuations across the sector are compelling, even more so if a number of subsectors can deliver revenues and earnings upgrades
Attractive valuations
There remains a robust, long-term growth outlook for the sector in contrast to many areas of the market currently
Long-term outlook
Macro-economic backdrop feels supportive given the prospect that financial conditions could tighten and economic activity could slow
Supportive backdrop
From across this diverse and broad sector, the Polar Capital Global Healthcare team are finding powerful growth stories, from disruptive biotech to global pharmaceuticals.
Discover more about how the healthcare sector is poised to benefit from a series of multi-year tailwinds, which point to a sustained healthcare bull market in the years to come.
Put healthcare at the heart of your portfolio
James Douglas, Fund Manager
James Douglas, PhD
Fund Manager
Damiano Soardo, CFA
Investment Analyst
Gareth Powell, CFA
Head of Healthcare
David Pinniger, CFA
Fund Manager
Deane Donnigan, PharmD
Fund Manager
Tara Raveendran, PhD
Consultant - Healthcare Research
Brett Pollard, PhD
Fund Manager
Academic qualifications
PhD and BSc (1st Class Hons) in Medicinal Chemistry, Newcastle University
Professional qualifications
ACCA diploma in financial management (DipFM)
Industry experience
25 years
Academic qualifications
MSc in Mathematics and Foundations of Computer Science, University of Oxford
Professional qualifications
CFA Charterholder
Industry experience
8 years
Academic qualifications
BSc in Cells and Systems Biology from the University of Oxford
Professional qualifications
Passed level 1 of the CFA
Industry experience
3 years
Academic qualifications
Studied cell and molecular biology at the University of St. Andrews; PhD in molecular virology
Professional qualifications
PhD
Industry experience
14 years
Academic qualifications
Doctor of Pharmacy (PharmD), Clinical Pharmacy, University of Georgia in conjunction with the Medical College of Georgia
Professional qualifications
Board certified and licensed pharmacist, ACCP board certified pharmacotherapy specialist, IMRO qualified
Industry experience
27 years
Academic qualifications
BA (1st Class Hons) in Human Sciences, University of Oxford
Professional qualifications
CFA Charterholder
Industry experience
24 years
Academic qualifications
MBiochem in Biochemistry, University of Oxford
Professional qualifications
CFA Charterholder
Industry experience
26 years
Tara joined Polar Capital in September 2021, as a consultant focused on independent research for the team. Prior to joining Polar Capital, she was the Head of Healthcare & Life Sciences Research at Shore Capital.
Investment Analyst
Tara Raveendran, PhD
Academic qualifications
BSc in Biochemistry and PhD in Structural Biology from Imperial College, London
Professional qualifications
PhD
Industry experience
18 years
Leanne Smith
Investment Analyst
Tara Raveendran, PhD Consultant - Healthcare Research
Leanne Smith
Investment Analyst
David joined Polar Capital in August 2013 as a portfolio manager within the Healthcare team, to launch the Polar Capital Biotechnology Fund. Prior to joining Polar Capital, David was portfolio manager of the International Biotechnology Trust at SV Life Sciences.
Previously, David spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm's venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector.
David Pinniger, CFA
Fund Manager
Tara joined Polar Capital in September 2021, as a consultant focused on independent research for the team. Prior to joining Polar Capital, she was the Head of Healthcare & Life Sciences Research at Shore Capital.
Tara Raveendran, PhD
Investment Analyst
Leanne joined the Polar Capital Healthcare Team as an Investment Analyst in October 2024. She started at the company in 2021 in the Client Services team as part of the Investment 20/20 scheme.
Leanne Smith
Investment Analyst
David joined Polar Capital in August 2013 as a portfolio manager within the Healthcare team, to launch the Polar Capital Biotechnology Fund. Prior to joining Polar Capital, David was portfolio manager of the International Biotechnology Trust at SV Life Sciences.
Previously, David spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm's venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector.
David Pinniger, CFA
Fund Manager
Gareth joined Polar Capital in 2007 to set up the Healthcare team. Prior to Polar Capital, Gareth worked at Framlington, where he began his career in investment management in 1999. Soon afterwards, he joined the Healthcare Team in 2001 and helped launch the Framlington Biotech Fund, which he managed from 2004 until his departure.
Gareth Powell, CFA
Head of Heathcare
James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.
Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma.
James Douglas, PhD
Fund Manager
David Pinniger, CFA
Fund Manager
Gareth Powell, CFA Head of Healthcare
James Douglas, PhD
Fund Manager
Damiano joined the Polar Capital Healthcare team as an investment analyst in October 2020. He started at the company in 2016 as part of the Operations team before moving to the Risk team in 2019. Prior to joining Polar Capital, he worked as a technical consultant at a fintech company. Damiano has an MSc in Mathematics and Foundations of Computer Science from the University of Oxford and is a CFA charterholder.
Damiano Soardo, CFA
Investment Analyst
Brett Pollard joined the Polar Capital Healthcare team in September 2021 as an investment analyst. Prior to Polar Capital, Brett was Managing Director of Strategy and Corporate Development at Scapa plc, with responsibility for investor relations. Since 2001 he has worked across the healthcare sector and within equity capital markets as a healthcare analyst, most recently at Numis, Brett also has worked in and led financial communications, corporate development, investor relations and operations.
Brett Pollard, PhD
Fund Manager
Deane joined Polar Capital in June 2013 and is the Lead Manager of the Polar Capital Healthcare Discovery Fund.
Prior to joining Polar Capital, Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen.
Deane Donnigan, PharmD
Fund Manager
Damiano Soardo, CFA
Investment Analyst
Brett Pollard, PhD
Fund Manager
Deane Donnigan, PharmD
Fund Manager
Source & Copyright: CITYWIRE. James Douglas has been awarded an A rating by Citywire for his 3 year risk-adjusted performance for the period 31/08/2021 - 31/08/2024.
FE Alpha Manager Ratings do not constitute investment advice offered by FE and should not be used as the sole basis for making any investment decision. © 2023 FE. All rights reserved.
Source & Copyright: CITYWIRE. David Pinniger has been awarded an AA rating by Citywire for his 3 year risk-adjusted performance for the period 31/08/2021 - 31/08/2024.
